ANI Pharmaceuticals reported strong third quarter results with top and bottom-line beats driven by double-digit growth in its Rare Disease and Generics segments. While total company revenue and EPS guidance were raised or tightened at the floor, management notably reduced the full-year outlook for Cortrophin Gel due to execution challenges in revenue conversion.
Key Highlights
- Top-Line Beat: Total net revenues reached $290.8 million, up 27.6% year-over-year, surpassing the consensus estimate of $280.3 million.
- Rare Disease Momentum: The segment grew 35.8% to $160.9 million, led by Cortrophin Gel revenues of $138.7 million (+36.1% YoY) and ILUVIEN revenues of $22.3 million (+34.1% YoY).
- Cortrophin Guidance Cut: Full-year Cortrophin Gel guidance was revised downward to $480–$500 million (from $520–$540 million), as capacity constraints in the specialty pharmacy network slowed the conversion of strong patient demand into therapy.
- Strategic Acquisition: The company announced a $560 million offer to acquire Egetis Therapeutics, which would add EMCITATE, a rare disease therapy with over $300 million in peak sales potential.
- Profitability and Buybacks: Adjusted non-GAAP diluted EPS of $2.70 grew 32.4% YoY, while the company repurchased $20 million in common stock year-to-date.